Applied Pharmacology for The Dental Hygienist 9th
| | | | | |
Edition by Elena Bablenis Haveles
| | | | |
Complete Test Bank
| |
,Chapter 01: Information Sources, Regulatory Agencies, Drug Legislation, and Prescription
| | | | | | | | |
Writing
|
Haveles: Applied Pharmacology for the Dental Hygienist, 9th Edition
| | | | | | | |
MULTIPLE |CHOICE
1. Knowledge |of |pharmacology |aids |the |dental |professional |in
a. obtaining |a |patient’s |health |history.
b. administering |drugs |in |the |office.
c. handling |emergency |situations.
d. selection |of |a |nonprescription |medication.
e. All |of |the |above.
ANS: | E
All |of |the |choices |are |true. |Because |many |of |our |patients |are |being |treated |with |drugs, |knowledge |of
|pharmacology |helps |in |understanding |and |interpreting |patients’ |responses |to |health |history |questions.
|Knowledge |of |the |therapeutic |and |adverse |effects |of |medications |obviously |helps |in |their |proper
|administration |in |the |office. |Emergency |situations |may |be |caused |by |drugs |or |treated |by |drugs; |thus,
|knowledge |of |pharmacology |is |of |great |help, |especially |because |a |rapid |response |is |sometimes
|required. |A |clear |understanding |of |the |concepts |of |drug |action, |drug |handling |by |the |body, |and |drug
|interactions |will |allow |the |dental |practitioner |to |make |proper |judgments |and |grasp |the |concepts
|relevant |to |new |drug |therapies |on |the |market.
DIF: Application
REF: | Role |of |the |Dental |Hygienist |(Medication/Health |History), |Role |of |the |Dental |Hygienist
|(Medication |Administration), |Role |of |the |Dental |Hygienist |(Emergency |Situations), |Role |of |the |Dental
|Hygienist |(Nonprescription |Medication) || |pp. |2-3 OBJ: 1
TOP: | NBDHE, |6.0. |Pharmacology
2. Which |of |the |following |statements |is |true |regarding |planning |appointments?
a. Whether |or |not |patients |are |taking |medication |for |systemic |diseases |is |of
little
|
consequence |in |the |dental |office.
b. Asthmatic |patients |should |have |dental |appointments |in |the |morning.
c. Diabetic |patients |usually |have |fewer |problems |with |a |morning |appointment
|compared |with |afternoon |appointments.
d. Both |B |and |C |are |true.
ANS: | D
Asthmatic |patients |who |experience |dental |anxiety |should |schedule |their |appointments |when |they |are
|not |rushed |or |under |pressure |early |in |the |morning. |Diabetic |patients |usually |have |relatively |fewer
|problems |with |a |morning |appointment. |Patients |taking |medication |for |systemic |diseases |may |require
|special |handling |in |the |dental |office.
DIF: Comprehension
REF: | Role |of |the |Dental |Hygienist |(Appointment |Scheduling) ||
|p. |3 |OBJ: | 1 TOP: | NBDHE, |6.0. |Pharmacology
,3. Nutritional |or |herbal |supplements
a. carry |the |U.S. |Food |and |Drug |Administration |(FDA) |approval |for |disease
states.
|
b. are |not |drugs.
c. can |cause |adverse |effects.
d. will |not |interact |with |other |drugs |the |patient |may |be |taking.
ANS: | C
Nutritional |or |herbal |supplements |are |quite |capable |of |causing |adverse |effects. |The |majority |of
|nutritional |or |herbal |supplements |do |not |carry |FDA |approval |for |treating |disease |states. |These
|supplements |are |drugs |and |can |cause |adverse |effects |and |interact |with |different |drugs.
DIF: Comprehension
REF: | Role |of |the |Dental |Hygienist |(Nutritional |or |Herbal |Supplements) ||
|p. |3 |OBJ: | 1 TOP: | NBDHE, |6.0. |Pharmacology
4. Which |type |of |drug |name |usually |begins |with |a |lowercase |letter?
a. Brand |name
b. Code |name
c. Generic |name
d. Trade |name
ANS: | C
Before |any |drug |is |marketed, |it |is |given |a |generic |name |that |becomes |the |“official” |name |of |the |drug.
|Each |drug |is |assigned |only |one |generic |name |selected |by |the |U.S. |Adopted |Name |Council, |and |the
|name |is |not |capitalized. |The |brand |name |is |equivalent |to |the |trade |name |and |is |capitalized.
|Although |the |brand |name |is |technically |the |name |of |the |company |marketing |the |product, |this |term |is
|often |used |interchangeably |with |the |trade |name. |The |code |name |is |the |initial |term |used |within |a
|pharmaceutical |company |to |refer |to |a |drug |while |it |is |undergoing |investigation |and |is |often |a
|combination |of |capital |letters |and |numbers, |the |letters |representing |an |abbreviation |of |the |company
|name.
DIF: Comprehension REF: | Drug |Names || |p.
|4 |OBJ: | 3 TOP: | NBDHE, |6.0. |Pharmacology
5. A |drug’s |generic |name |is |selected |by |the
a. pharmaceutical |company |manufacturing |it.
b. Food |and |Drug |Administration |(FDA).
c. U.S. |Adopted |Name |Council.
d. Federal |Patent |Office.
ANS: | C
Each |drug |is |assigned |only |one |generic |name |(e.g., |ibuprofen). |It |is |selected |by |the |U.S. |Adopted
|Name |Council. |The |generic |name |is |not |selected |by |the |FDA |or |the |Federal |Patent |Office. |The
|pharmaceutical |company |manufacturing |the |drug |clearly |has |an |influence |on |the |generic |name |given
|its |drug, |but |the |final |decision |is |not |the |company’s.
DIF: Recall REF: | Drug |Names || |p. |4 OBJ:
| 3 |TOP: | NBDHE, |6.0. |Pharmacology
6. Which |of |the |following |is |true |concerning |generic |and |trade |names |of |drugs?
a. A |drug |may |only |have |one |generic |name |and |one |trade
name.
|
, b. A |drug |may |only |have |one |generic |name, |but |it |may |have |several |trade
names.
|
c. A |drug |may |have |several |generic |names, |but |it |may |only |have |one |trade
|name.
d. A |drug |may |have |several |generic |names |and |several |trade |names.
ANS: | B
Each |drug |has |only |one |generic |name |but |may |have |several |trade |names. |For |each |drug, |there |is |only
|one |generic |name. |It |is |not |capitalized, |and |it |becomes |the |“official” |name |of |the |drug. |The
|pharmaceutical |company |discovering |the |drug |gives |the |drug |a |trade |name. |The |trade |name |is
|protected |by |the |Federal |Patent |Law |for |20 |years |from |the |earliest |claimed |filing |date, |plus |patent
|term |extensions. |Although |the |brand |name |is |technically |the |name |of |the |company |marketing |the
|product, |it |is |often |used |interchangeably |with |the |trade |name.
DIF: Comprehension REF: | Drug |Names || |p.
|4 |OBJ: | 3 TOP: | NBDHE, |6.0. |Pharmacology
7. Two |drugs |that |are |found |to |be |chemically |equivalent, |but |not |biologically |equivalent |or
therapeutically |equivalent |are |said |to |differ |in
|
a. potency.
b. efficacy.
c. bioavailability.
d. therapeutic |index.
ANS: | C
A |preparation |can |be |chemically |equivalent |yet |not |biologically |or |therapeutically |equivalent. |These
|products |are |said |to |differ |in |their |bioavailability. |The |potency |of |a |drug |is |a |function |of |the |amount
|of |drug |required |to |produce |an |effect. |The |efficacy |is |the |maximum |intensity |of |effect |or |response
|that |can |be |produced |by |a |drug. |The |therapeutic |index |is |the |ratio |of |the |lethal |dose |for |50% |of |the
|experimental |animals |divided |by |the |effective |dose |for |50% |of |the |experimental |animals. |If |the
|value |of |the |therapeutic |index |is |small, |toxicity |is |more |likely.
DIF: Recall REF: | Drug |Names |(Drug |Substitution) || |p.
|5 |OBJ: | 4 TOP: | NBDHE, |6.0. |Pharmacology
8. How |many |years |must |pass |after |a |drug |patent |expires |before |other |drug |companies |can |market
the |same |compound |as |a |generic |drug?
|
a. 20 |years
b. 17 |years
c. 7 |years
d. 0 |years
ANS: | D
Once |a |drug |patent |expires, |competing |companies |may |immediately |market |the |same |compound |in
|generic |form. |The |pharmaceutical |company |discovering |the |drug |gives |the |drug |a |trade |name. |The
|trade |name |is |protected |by |the |Federal |Patent |Law |for |20 |years |from |the |earliest |claimed |filing |date,
|plus |the |patent |term |extensions.
DIF: Application REF: | Drug |Names |(Drug |Substitution) || |p.
|5 |OBJ: | 4 TOP: | NBDHE, |6.0. |Pharmacology
| | | | | |
Edition by Elena Bablenis Haveles
| | | | |
Complete Test Bank
| |
,Chapter 01: Information Sources, Regulatory Agencies, Drug Legislation, and Prescription
| | | | | | | | |
Writing
|
Haveles: Applied Pharmacology for the Dental Hygienist, 9th Edition
| | | | | | | |
MULTIPLE |CHOICE
1. Knowledge |of |pharmacology |aids |the |dental |professional |in
a. obtaining |a |patient’s |health |history.
b. administering |drugs |in |the |office.
c. handling |emergency |situations.
d. selection |of |a |nonprescription |medication.
e. All |of |the |above.
ANS: | E
All |of |the |choices |are |true. |Because |many |of |our |patients |are |being |treated |with |drugs, |knowledge |of
|pharmacology |helps |in |understanding |and |interpreting |patients’ |responses |to |health |history |questions.
|Knowledge |of |the |therapeutic |and |adverse |effects |of |medications |obviously |helps |in |their |proper
|administration |in |the |office. |Emergency |situations |may |be |caused |by |drugs |or |treated |by |drugs; |thus,
|knowledge |of |pharmacology |is |of |great |help, |especially |because |a |rapid |response |is |sometimes
|required. |A |clear |understanding |of |the |concepts |of |drug |action, |drug |handling |by |the |body, |and |drug
|interactions |will |allow |the |dental |practitioner |to |make |proper |judgments |and |grasp |the |concepts
|relevant |to |new |drug |therapies |on |the |market.
DIF: Application
REF: | Role |of |the |Dental |Hygienist |(Medication/Health |History), |Role |of |the |Dental |Hygienist
|(Medication |Administration), |Role |of |the |Dental |Hygienist |(Emergency |Situations), |Role |of |the |Dental
|Hygienist |(Nonprescription |Medication) || |pp. |2-3 OBJ: 1
TOP: | NBDHE, |6.0. |Pharmacology
2. Which |of |the |following |statements |is |true |regarding |planning |appointments?
a. Whether |or |not |patients |are |taking |medication |for |systemic |diseases |is |of
little
|
consequence |in |the |dental |office.
b. Asthmatic |patients |should |have |dental |appointments |in |the |morning.
c. Diabetic |patients |usually |have |fewer |problems |with |a |morning |appointment
|compared |with |afternoon |appointments.
d. Both |B |and |C |are |true.
ANS: | D
Asthmatic |patients |who |experience |dental |anxiety |should |schedule |their |appointments |when |they |are
|not |rushed |or |under |pressure |early |in |the |morning. |Diabetic |patients |usually |have |relatively |fewer
|problems |with |a |morning |appointment. |Patients |taking |medication |for |systemic |diseases |may |require
|special |handling |in |the |dental |office.
DIF: Comprehension
REF: | Role |of |the |Dental |Hygienist |(Appointment |Scheduling) ||
|p. |3 |OBJ: | 1 TOP: | NBDHE, |6.0. |Pharmacology
,3. Nutritional |or |herbal |supplements
a. carry |the |U.S. |Food |and |Drug |Administration |(FDA) |approval |for |disease
states.
|
b. are |not |drugs.
c. can |cause |adverse |effects.
d. will |not |interact |with |other |drugs |the |patient |may |be |taking.
ANS: | C
Nutritional |or |herbal |supplements |are |quite |capable |of |causing |adverse |effects. |The |majority |of
|nutritional |or |herbal |supplements |do |not |carry |FDA |approval |for |treating |disease |states. |These
|supplements |are |drugs |and |can |cause |adverse |effects |and |interact |with |different |drugs.
DIF: Comprehension
REF: | Role |of |the |Dental |Hygienist |(Nutritional |or |Herbal |Supplements) ||
|p. |3 |OBJ: | 1 TOP: | NBDHE, |6.0. |Pharmacology
4. Which |type |of |drug |name |usually |begins |with |a |lowercase |letter?
a. Brand |name
b. Code |name
c. Generic |name
d. Trade |name
ANS: | C
Before |any |drug |is |marketed, |it |is |given |a |generic |name |that |becomes |the |“official” |name |of |the |drug.
|Each |drug |is |assigned |only |one |generic |name |selected |by |the |U.S. |Adopted |Name |Council, |and |the
|name |is |not |capitalized. |The |brand |name |is |equivalent |to |the |trade |name |and |is |capitalized.
|Although |the |brand |name |is |technically |the |name |of |the |company |marketing |the |product, |this |term |is
|often |used |interchangeably |with |the |trade |name. |The |code |name |is |the |initial |term |used |within |a
|pharmaceutical |company |to |refer |to |a |drug |while |it |is |undergoing |investigation |and |is |often |a
|combination |of |capital |letters |and |numbers, |the |letters |representing |an |abbreviation |of |the |company
|name.
DIF: Comprehension REF: | Drug |Names || |p.
|4 |OBJ: | 3 TOP: | NBDHE, |6.0. |Pharmacology
5. A |drug’s |generic |name |is |selected |by |the
a. pharmaceutical |company |manufacturing |it.
b. Food |and |Drug |Administration |(FDA).
c. U.S. |Adopted |Name |Council.
d. Federal |Patent |Office.
ANS: | C
Each |drug |is |assigned |only |one |generic |name |(e.g., |ibuprofen). |It |is |selected |by |the |U.S. |Adopted
|Name |Council. |The |generic |name |is |not |selected |by |the |FDA |or |the |Federal |Patent |Office. |The
|pharmaceutical |company |manufacturing |the |drug |clearly |has |an |influence |on |the |generic |name |given
|its |drug, |but |the |final |decision |is |not |the |company’s.
DIF: Recall REF: | Drug |Names || |p. |4 OBJ:
| 3 |TOP: | NBDHE, |6.0. |Pharmacology
6. Which |of |the |following |is |true |concerning |generic |and |trade |names |of |drugs?
a. A |drug |may |only |have |one |generic |name |and |one |trade
name.
|
, b. A |drug |may |only |have |one |generic |name, |but |it |may |have |several |trade
names.
|
c. A |drug |may |have |several |generic |names, |but |it |may |only |have |one |trade
|name.
d. A |drug |may |have |several |generic |names |and |several |trade |names.
ANS: | B
Each |drug |has |only |one |generic |name |but |may |have |several |trade |names. |For |each |drug, |there |is |only
|one |generic |name. |It |is |not |capitalized, |and |it |becomes |the |“official” |name |of |the |drug. |The
|pharmaceutical |company |discovering |the |drug |gives |the |drug |a |trade |name. |The |trade |name |is
|protected |by |the |Federal |Patent |Law |for |20 |years |from |the |earliest |claimed |filing |date, |plus |patent
|term |extensions. |Although |the |brand |name |is |technically |the |name |of |the |company |marketing |the
|product, |it |is |often |used |interchangeably |with |the |trade |name.
DIF: Comprehension REF: | Drug |Names || |p.
|4 |OBJ: | 3 TOP: | NBDHE, |6.0. |Pharmacology
7. Two |drugs |that |are |found |to |be |chemically |equivalent, |but |not |biologically |equivalent |or
therapeutically |equivalent |are |said |to |differ |in
|
a. potency.
b. efficacy.
c. bioavailability.
d. therapeutic |index.
ANS: | C
A |preparation |can |be |chemically |equivalent |yet |not |biologically |or |therapeutically |equivalent. |These
|products |are |said |to |differ |in |their |bioavailability. |The |potency |of |a |drug |is |a |function |of |the |amount
|of |drug |required |to |produce |an |effect. |The |efficacy |is |the |maximum |intensity |of |effect |or |response
|that |can |be |produced |by |a |drug. |The |therapeutic |index |is |the |ratio |of |the |lethal |dose |for |50% |of |the
|experimental |animals |divided |by |the |effective |dose |for |50% |of |the |experimental |animals. |If |the
|value |of |the |therapeutic |index |is |small, |toxicity |is |more |likely.
DIF: Recall REF: | Drug |Names |(Drug |Substitution) || |p.
|5 |OBJ: | 4 TOP: | NBDHE, |6.0. |Pharmacology
8. How |many |years |must |pass |after |a |drug |patent |expires |before |other |drug |companies |can |market
the |same |compound |as |a |generic |drug?
|
a. 20 |years
b. 17 |years
c. 7 |years
d. 0 |years
ANS: | D
Once |a |drug |patent |expires, |competing |companies |may |immediately |market |the |same |compound |in
|generic |form. |The |pharmaceutical |company |discovering |the |drug |gives |the |drug |a |trade |name. |The
|trade |name |is |protected |by |the |Federal |Patent |Law |for |20 |years |from |the |earliest |claimed |filing |date,
|plus |the |patent |term |extensions.
DIF: Application REF: | Drug |Names |(Drug |Substitution) || |p.
|5 |OBJ: | 4 TOP: | NBDHE, |6.0. |Pharmacology
